Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients With Monoclonal IgG or IgA Paraprotein Expression
Document Type
Article
Publication Title
Leukemia & Lymphoma
Abstract
Lymphoplasmacytic lymphoma secreting IgG or IgA (non-IgM LPL) is rarely seen. Systematic studies of the clinical features and treatment outcomes are lacking in these patients. This study evaluated 17 patients with non-IgM LPL. The paraprotein secreted by these tumors was IgA (n=8; 47%) and IgG (n=9; 53%). The median serum level of paraprotein was 2,475 mg/dl (range=747-5260) for IgA and 2580 mg/dl (range=1900-7100) for IgG. The IgA-LPL group was more likely to present with B symptoms, a high beta2-microglobulin level and extramedullary involvement. Compared with patients with Waldenström macroglobulinemia (WM), patients with non-IgM LPL showed similar clinical and pathologic features, but a higher mortality within the first year after diagnosis (p
DOI
10.3109/10428194.2015.1096357
Publication Date
5-2016
Keywords
IgA, IgG, Lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, non-IgM, prognosis, treatment
ISSN
1029-2403
Recommended Citation
Cao X, Medeiros L, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette Z, Orlowski RZ, Young KH. Clinicopathologic Features and Outcomes of Lymphoplasmacytic Lymphoma Patients With Monoclonal IgG or IgA Paraprotein Expression. Leukemia & Lymphoma. 2016; 57(5). doi: 10.3109/10428194.2015.1096357.